



## Christopher T Chen, MD

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

### CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic E

Stanford, CA 94305

Tel (650) 725-5421

Fax (650) 723-8748

### Bio

---

#### BIO

Dr. Chen is a board-certified, fellowship-trained specialist in oncology and hematology. He is also an Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

Dr. Chen delivers comprehensive, compassionate care for patients in need of early drug development clinical trials and patients with gastrointestinal cancers. As a researcher, he leads the early drug development group and studies how tumor heterogeneity limits the clinical benefit of anticancer therapies in order to accelerate development of novel therapeutic strategies. Dr. Chen's work has appeared in the New England Journal of Medicine, JAMA, Journal of Clinical Oncology, Science Advances, Journal of Oncology Practice, and Health Services Research.

Dr. Chen attended Harvard College, where he graduated summa cum laude and Phi Beta Kappa in molecular biology. He went to medical school at Washington University in St. Louis on a full-tuition merit scholarship, graduating with Alpha Omega Alpha honors, and did his residency training in internal medicine at Massachusetts General Hospital and hematology/oncology fellowship in the combined Harvard Dana-Farber Cancer Institute/Massachusetts General Hospital program. As a fellow, he received the NIH T-32 Ruth L. Kirchstein-National Service Research Award in Cancer Biology for his work exploring the molecular structure of metastatic solid tumors.

Dr. Chen is a member of the American Society of Clinical Oncology and European Society for Medical Oncology. He is an associate member of the American Association for Cancer Research.

#### CLINICAL FOCUS

- Developmental Therapeutics
- GI Oncology
- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Oncology

## ADMINISTRATIVE APPOINTMENTS

- Clinical Director, Early Drug Development, Stanford Cancer Institute, (2021- present)

## HONORS AND AWARDS

- Andrea Lynn Scott Memorial Research Fellowship, Cholangiocarcinoma Foundation (2021-2022)
- FDA-AACR Oncology Education Fellow, FDA / AACR (2020-2021)
- T32 Ruth L. Kirschstein-National Service Research Award in Cancer Biology, NIH (2018-2020)

## PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2020)
- Board Certification: Hematology, American Board of Internal Medicine (2020)
- Board Certification, American Board of Internal Medicine , Medical Oncology (2020)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2020) MA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2017)
- Residency: Massachusetts General Hospital Internal Medicine Residency (2017) MA
- Medical Education: Washington University in St Louis Registrar (2014) MO
- BA, Harvard College , Molecular Biology, Economics, Health Policy (2010)

## Publications

---

### PUBLICATIONS

- **Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy.** *JCO precision oncology*  
Stamou, M. I., Chen, C., Wander, S. A., Supko, J. G., Juric, D., Bardia, A., Wexler, D. J.  
2022; 6: e2100428
- **A Novel Framework for the Next Generation of Precision Oncology Targets.** *JAMA oncology*  
Chen, C. T., Ford, J. M.  
2022
- **Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX)**  
Pollom, E. L., Shelton, A., Fisher, G. A., Bien, J., King, D., Johnson, T., Chen, C., Shaheen, S., Chong, C., Vitzthum, L., Kirilcuk, N., Morris, A. M., Kin, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+gastrointestinal cancers (trial in progress)**  
Park, H., Bekaii-Saab, T. S., Kim, S. S., Kamath, S., Pishvaian, M. J., Chen, C., Zhen, D., Mayor, J., Tan, Q., Strickler, J. H.  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Paving a pathway for drug development in HER2-positive biliary tract cancer.** *The Lancet. Oncology*  
Chen, C. T., Goyal, L.  
2021; 22 (9): 1204-1206
- **A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.**  
Puzanov, I., LoRusso, P., Papadopoulos, K. P., Chen, C. T., LeBruchec, Y., He, X., Cousin, T., Havenith, K., Boni, J., Bendell, J. C.  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma.** *The New England journal of medicine*  
Goyal, L. n., Chen, C. T., Pierce, T. T., Deshpande, V. n.  
2021; 384 (11): 1054-64
- **Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.** *Nature communications*

- Pereira, B., Chen, C. T., Goyal, L., Walmsley, C., Pinto, C. J., Baiev, I., Allen, R., Henderson, L., Saha, S., Reyes, S., Taylor, M. S., Fitzgerald, D. M., Broudo, et al 2021; 12 (1): 3199
- **Characterization of spatial and temporal heterogeneity of ER positive metastatic breast cancer using serial biopsies**  
Allen, R. K., Pinto, C. J., Fitzgerald, D. M., Huynh, T. G., Chen, C. T., Juric, D.  
AMER ASSOC CANCER RESEARCH.2020
  - **Plasma sequencing demonstrates that breast cancer patients have a higher prevalence of clonal and multiple PIK3CA mutations than other solid tumor patients**  
Chen, C., Sahu, A., Price, K., Pinto, C., Allen, R., Wang, X., Szabolcs, A., Goyal, L., Ting, D., Liu, S., Juric, D.  
AMER ASSOC CANCER RESEARCH.2020
  - **Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Chen, C. n., Di Bartolomeo, M. n., Corallo, S. n., Strickler, J. H., Goyal, L. n.  
2020; 40: 161–73
  - **Response rates and lesion-level progression patterns of solid tumor patients in an academic phase I program: implications for tumour heterogeneity**  
Chen, C., Pinto, C., Walmsley, C., Allen, R., Muzikansky, A., Henderson, L., Broudo, M., Wolfgang, J., Fitzgerald, D. M., Hong, T., Juric, D.  
OXFORD UNIV PRESS.2019
  - **Pharmacological inhibition of  $\beta$ -catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.** *Science advances*  
Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Rafi, S., Zhu, A. X., Feng, et al  
2019; 5 (5): eaau5240
  - **Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Hwang, T. J., Franklin, J. M., Chen, C. T., Lauffenburger, J. C., Gyawali, B., Kesselheim, A. S., Darrow, J. J.  
2018; 36 (18): 1805-1812
  - **Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death.** *Health services research*  
Chen, C. T., Li, L. n., Brooks, G. n., Hassett, M. n., Schrag, D. n.  
2018; 53 (4): 2118–32
  - **Walk-in clinics versus physician offices and emergency rooms for urgent care and chronic disease management.** *Cochrane database of systematic reviews*  
Chen, C. E., Chen, C. T., Hu, J., Mehrotra, A.  
2017; 2: CD011774-?
  - **Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.** *Journal of oncology practice*  
Chen, C. T., Kesselheim, A. S.  
2017; 13 (6): 352–55
  - **Transforming healthcare delivery: Why and how accountable care organizations must evolve.** *Journal of hospital medicine*  
Chen, C. T., Ackerly, D. C., Gottlieb, G. n.  
2016; 11 (9): 658–61
  - **Disruptive innovation in academic medical centers: balancing accountable and academic care.** *Academic medicine : journal of the Association of American Medical Colleges*  
Stein, D. n., Chen, C. n., Ackerly, D. C.  
2015; 90 (5): 594–98
  - **Readmission penalties and health insurance expansions: a dispatch from Massachusetts.** *Journal of hospital medicine*  
Chen, C., Scheffler, G., Chandra, A.  
2014; 9 (11): 681-7
  - **Beyond ACOs and bundled payments: Medicare's shift toward accountability in fee-for-service.** *JAMA*  
Chen, C. n., Ackerly, D. C.  
2014; 311 (7): 673–74
  - **Massachusetts' health care reform and emergency department utilization.** *The New England journal of medicine*

Chen, C., Scheffler, G., Chandra, A.  
2011; 365 (12): e25